Oncology News Central company information, Employees & Contact Information

“A Real Insult”: Oncologists Outraged Over Downcoding Policy Oncology News Central

DESTINY-Breast11 Data at ESMO 2025 Back Neoadjuvant T-DXd-THP in High-Risk Early Breast Cancer Oncology News Central

FDA Expands Selumetinib Use to Younger Children With NF1 Tumors Oncology News Central

Oncologist Conquers Prestigious Marathons, Sees Parallels Between Running and Cancer Care Oncology News Central

Frustration Emerges as Pivotal Breast Cancer Trial Leaves Many Unanswered Questions Oncology News Central

Bladder Cancer Trial “Knocked It Out of the Park,” Expert Says Oncology News Central

“Compelling” Overall Survival Data Back Osimertinib Plus Chemo as First-Line Standard in EGFR-Mutated NSCLC Oncology News Central

Community Cancer Is “Like a Hostage” in CMS Payment Negotiations Oncology News Central

FDA Approves Subcutaneous Pembrolizumab for Solid Tumors Oncology News Central

Oncologists Likely Unaware That Popular Supplement Is Hindering Cancer Care Oncology News Central

Interest in Ivermectin for Cancer “Has Spread Like Wildfire,” Oncologists Say Oncology News Central

What the Death of Letters to the Editor Means for Oncology Oncology News Central

In the “Long Game” of Follicular Lymphoma Care, Quality of Life Is Key Oncology News Central

EHR-Based Intervention Helps Advanced Cancer Patients Stay Out of the Hospital, Real-World Study Finds Oncology News Central

Oncologist Shortage “Far More Desperate” in Some Areas, as Researchers Look for Solutions Oncology News Central

Fallout From Failed Phase 3 Trial: Adjuvant Therapy “Not the Most Appropriate Option” for All Stage III Melanomas Oncology News Central

Oncology Drugs Fast-Tracked by the FDA in June 2025 Oncology News Central

Why Community Oncologists Should Support Proposed AI Legislation Oncology News Central

“Quite Extraordinary Results” for Novel TKI in HER2-Mutated NSCLC Trial Oncology News Central

Getting Americans to Support Cancer Research May Take a New Message, Oncology Leader Says Oncology News Central

“It Unlocks This Whole World”: Better Understanding of Lung Cancer Is Generating Better Outcomes Oncology News Central

First-of-Its-Kind Trial Shows CAR-T Outperforms Standard Treatments in Gastric Cancer Oncology News Central

Cannabis in Community Cancer Care: Where Do Things Stand? Oncology News Central

Practice Change in Advanced Colorectal Cancer: Combination Outperforms Chemo for Survival Oncology News Central

24 Books Oncologists Should Read This Summer, According to Their Colleagues Oncology News Central

No Survival Benefit With Addition of Venetoclax to Azacitidine in Intermediate-, High-Risk MDS Oncology News Central

“Milestone” in EGFR-Positive NSCLC: The Importance of Options for Patient-Centered Care Oncology News Central

Public Dollars, Private Profits? Cancer Drug’s Cost Sky High Despite Taxpayer Funding Oncology News Central

Oncologists Face Unique Challenges With Older Cancer Patients Oncology News Central

FDA Acts on 6 ADCs in Oncology: Rapid News Roundup Oncology News Central

“Important Milestone”: Perioperative Durvalumab Improves Event-Free Survival in Gastric Cancer Oncology News Central

“Remarkable” Survival Data for ADC Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Oncology News Central

Cancer Vaccines Finally Reach Turning Point, Says Expert Oncology News Central

What Does the Biggest Breast Cancer News From ASCO 2025 Mean for Practice Right Now? Oncology News Central

FDA Grants Accelerated Approval for Linvoseltamab for Relapsed Myeloma Oncology News Central

2025-2026 US News & World Report Cancer Center Rankings Oncology News Central

Head-to-Head Trial Establishes T-DXd (Enhertu) as Superior Second-Line Treatment for Some Gastric, GEJ Cancers Oncology News Central

“Highly Urgent”: Oncologists Must Get Up to Speed on Subcutaneous Cancer Drugs, Expert Warns Oncology News Central

Why Oncologists Should “Get Over That Fear” of Using Targeted Breast Cancer Drugs Oncology News Central

Phase 3 Win, New Guidelines, and More: Lung Cancer News Rapid Roundup Oncology News Central

Thanks to Big Survival Data, 2025 “One of the Best Years” for Progress in SCLC Oncology News Central

What’s the Right Dose and Duration for EV-Pembro in Bladder Cancer? Oncology News Central

NCI Program on Dog-to-Human Cancer Drug Development Focus of TV Series Oncology News Central

Game-Changing SCLC Drug Hits Clinics: What’s the Playbook for Community Oncology? Oncology News Central

ASCO’s Updated Mesothelioma Guidelines: What Oncologists Should Know Oncology News Central

What Community Oncologists Should Know About “Bellwether” for PBM Reform Oncology News Central

Managing Toxicities Associated With New Targeted Gastric Cancer Therapies Oncology News Central

“Positive” Cancer Trials With Surrogate Endpoints Rarely Improve Survival, Quality of Life Oncology News Central

Phase 3 Breast Cancer Trial Shows PFS Benefit in ctDNA-Guided Treatment Ahead of Disease Progression Oncology News Central

Clinical Trials in Community Oncology: Demand High for More Studies and Patients Oncology News Central

FDA Fully Approves Larotrectinib for NTRK-Positive Solid Tumors Oncology News Central

Oncologists Turn to Off-Label Drug Use for Rare Cancers: What to Know Oncology News Central

FDA Rejects Oncolytic Virus Combination for Advanced Melanoma Oncology News Central

Amid Surge in Early-Onset Colorectal Cancer, Significant Disparities Found Oncology News Central

Will Generational Divide Among Oncologists Affect How AI Changes Cancer Care? Oncology News Central

Top Melanoma Abstracts from ASCO 2025 Oncology News Central

Tumor-Agnostic Trial Finds PARP Inhibitor and Anti-PD-L1 Combo Beneficial Across Cancer Types Oncology News Central

ASCO 2025: Which Studies Are Likely to Change Practice? Oncology News Central

With DEI in the Crosshairs, ACS Forges Ahead With Ambitious Study of Black Women Oncology News Central

FDA Approves Nivolumab (Opdivo) Plus Ipilimumab (Yervoy) for Advanced Colorectal Cancer Oncology News Central

Major Cancer Centers Hit With Layoffs, Hiring Freezes After Federal Cuts Oncology News Central

FDA Rejects Rivoceranib Plus Camrelizumab for Liver Cancer for the Second Time Oncology News Central

Oncology Drugs Fast-Tracked by the FDA in February 2025 Oncology News Central

Big Phase 3 Wins in Lung Cancer and More: Antibody-Drug Conjugate News Rapid Roundup Oncology News Central

Investigational Drug Combo Posts Strong Efficacy, Safety Data in First-Line Advanced NSCLC Trial Oncology News Central

Practice Changes and “Provocative” Data: Top Lung Cancer Stories From ASCO 2025 Oncology News Central

Community Oncology Is at a Tipping Point Thanks to Consolidation, Policy Problems Oncology News Central

After Years of Inactivity, “Dizzying” Changes Hit Bladder Cancer Care Oncology News Central

Adjuvant Cell Therapy Reduces Recurrence Risk in Early-Stage Liver Cancer Oncology News Central

Cancer Care Quality Declined After Hospital’s Acquisition, Study Finds Oncology News Central

Match Day Numbers Show “Promising” Change in Radiation Oncology Oncology News Central

Challenging Clinical Case: A 43-Year-Old Woman With Early-Stage Breast Cancer Oncology News Central

Antihistamines Tied to Survival Benefit With Immunotherapy in Bladder Cancer Study Oncology News Central

Subcutaneous Drug Delivery Is Changing Oncology for Clinicians and Patients Oncology News Central

Top 10 Ways Apps Are Helping Oncologists Oncology News Central

Mevrometostat Combo Posts Strong Data in Early-Phase Prostate Cancer Trial Oncology News Central

Oncology Should Avoid Mandatory Value-Based Care Payment Models Oncology News Central

Surprise Failure in Phase 3 Lung Cancer Trial: Combo Regimen Misses Dual Endpoints Oncology News Central

When ESR1 Mutations Arise in Breast Cancer Patients With PIK3CA Mutations: What Next? Oncology News Central

Subcutaneous Nivolumab Reduces Burden of Melanoma Care, Expert Says Oncology News Central

FDA Approves Tislelizumab-jsgr (Tevimbra) Combo for Gastric or Gastroesophageal Junction Cancer Oncology News Central

FDA Approves Subcutaneous Nivolumab (Opdivo Qvantig) for All Solid Tumor Indications Oncology News Central

FDA Grants Accelerated Approval to Encorafenib (Braftovi) Combination for Metastatic Colorectal Cancer Oncology News Central

ASCO President Speaks Out on “Huge Problem” of Oncologist Burnout Oncology News Central

Low-Dose Aspirin Halves Recurrence in Some Colorectal Cancers Oncology News Central

Unethical Behavior by Oncologists Presents Challenge Oncology News Central

$42 Million in Cancer Care Claim Errors: See Where Oncologists Made Mistakes Oncology News Central

1 in 4 Cancer Radiotherapy Plans Change After Peer Review Oncology News Central

Biomarkers Linked to Pathologic Response in Early Triple-Negative Breast Cancer Oncology News Central

Cancer-Causing Chemical Spurs Second, Bigger Recall of Duloxetine (Cymbalta) Oncology News Central

Path to Cure in CLL? Long-Term Data Highlight CAR-T Therapy’s Durable Responses Oncology News Central

Trastuzumab Deruxtecan (Enhertu) Beats Chemotherapy in PFS for HER2-Low Metastatic Breast Cancer Oncology News Central

Standard-of-Care Shift in Advanced Kidney Cancer Introduces Questions for Some Patients Oncology News Central

After Sacituzumab Govitecan (Trodelvy) Pulled in Bladder Cancer, What Now? Oncology News Central

Oncologists Left Needing Guidance After FDA-Approved Drugs Fail Confirmatory Trials Oncology News Central

Treatment Guide for Pembrolizumab (Keytruda) for Endometrial Cancer Oncology News Central

Oncology Drug Report 2024 Oncology News Central

Oncology Drugs Fast-Tracked by the FDA in October 2024 Oncology News Central

Cancer Care, Oncology Drug Development Hurt by Inflation Reduction Act? Oncology News Central

FDA Urged to Levy Fines for Delayed Confirmatory Trials in Oncology and Beyond Oncology News Central